# INMB — INmune Bio Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** INMB  
**Sources:** 20  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-inmb-inmune-bio-inc-catalysts-narrative-risks-10502

---

# INmune Bio Inc. (NASDAQ: INMB) — Company Snapshot (as of ~Oct 31, 2026)

INmune Bio is a pre-revenue, clinical-stage immunology/biotechnology company headquartered in Boca Raton, Florida, developing therapies that target the innate immune system for diseases such as Alzheimer's, cancer, and immune-mediated conditions [[11]](https://www.marketbeat.com/earnings/reports/2026-11-5-inmune-bio-inc-stock/), [[20]](https://www.inmunebio.com/index.php/investors). It trades on Nasdaq under INMB. As of Oct 30, 2026 the stock closed at ~$1.45 (down 9.38% that day), with a market cap of ~$44.4–44.9M, a 52-week range of $1.09–$2.60, and total cash of ~$18.4M [[8]](https://stockanalysis.com/stocks/inmb/forecast/), [[9]](https://tickernerd.com/stock/inmb-forecast/), [[19]](https://finance.yahoo.com/quote/INMB/).

---

## Recent Catalysts (roughly Aug–Oct 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-inmb-inmune-bio-inc-catalysts-narrative-risks-10502 (free to sign up)._